Lufuno Grace Mavhandu

Dr. Lufuno Grace Mavhandu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2018 in Viruses
Verified
Journal Article
Open access
PDF file
EEElizabeth M. Etta
Elizabeth M. Etta
DADOYINMOLA PAUL ALAYANDE
DOYINMOLA PAUL ALAYANDE
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
GGGeorge Gachara
George Gachara
PBPascal Bessong
Pascal Bessong
Human herpes virus type 8 (HHV-8) is the causative agent of Kaposi’s sarcoma (KS). We systematically reviewed literature published between 1998 and 2017, according to the PRISMA guidelines, to understand the distribution of HHV-8 infection in Africa. More than two-thirds (64%) of studies reported on seroprevalence and 29.3% on genotypes; 9.5% were on both seroprevalence and genotypes. About 45% of African countries had data on HHV-8 seroprevalence exclusively, and more than half (53%) had data on either seroprevalence or genotypes. Almost half (47%) of the countries had no data on HHV-8 infection. There was high heterogeneity in the types of tests and interpretation algorithms used in determining HHV-8 seropositivity across the different studies. Generally, seroprevalence ranged from 2.0% in a group of young children in Eritrea to 100% in a small group of individuals with KS in Central African Republic, and in a larger group of individuals with KS in Morocco. Approximately 16% of studies reported on children. Difference in seroprevalence across the African regions was not significant (95% CI, χ2 = 0.86; p = 0.35), although specifically a relatively significant level of infection was observed in HIV-infected children. About 38% of the countries had data on K1 genotypes. K1 genotypes A, A5, B, C, F and Z occurred at frequencies of 5.3%, 26.3%, 42.1%, 18.4%, 5.3% and 2.6%, respectively. Twenty-three percent of the countries had data for K15 genotypes, and genotypes P, M and N occurred at frequencies of 52.2%, 39.1%, and 8.7%, respectively. Data on HHV-8 inter-genotype recombinants in Africa are scanty. HHV-8 may be endemic in the entire Africa continent but there is need for a harmonized testing protocol for a better understanding of HHV-8 seropositivity. K1 genotypes A5 and B, and K15 genotypes P and M, from Africa, should be considered in vaccine design efforts.

8 March 2017 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
GGGeorge Gachara
George Gachara
TMTshifhiwa Magoro
Tshifhiwa Magoro
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
ELEmmaculate Lum
Emmaculate Lum
HKHelen K. Kimbi
Helen K. Kimbi
PBPascal Bessong
Pascal Bessong
Occult hepatitis B infection (OBI) among HIV positive patients varies widely in different geographic regions. We undertook a study to determine the prevalence of occult hepatitis B infection among HIV infected individuals visiting a health facility in South West Cameroon and characterized occult HBV strains based on sequence analyses. Plasma samples (n = 337), which previously tested negative for hepatitis B surface antigen (HBsAg), were screened for antibodies against hepatitis B core (anti-HBc) and surface (anti-HBs) antigens followed by DNA extraction. A 366 bp region covering the overlapping surface/polymerase gene of HBV was then amplified in a nested PCR and the amplicons sequenced using Sanger sequencing. The resulting sequences were then analyzed for genotypes and for escape and drug resistance mutations. Twenty samples were HBV DNA positive and were classified as OBI giving a prevalence of 5.9%. Out of these, 9 (45%) were anti-HBs positive, while 10 (52.6%) were anti-HBc positive. Additionally, 2 had dual anti-HBs and anti-HBc reactivity, while 6 had no detectable HBV antibodies. Out of the ten samples that were successfully sequenced, nine were classified as genotype E and one as genotype A. Three sequences possessed mutations associated with lamivudine resistance. We detected a number of mutations within the major hydrophilic region of the surface gene where most immune escape mutations occur. Findings from this study show the presence of hepatitis B in patients without any of the HBV serological markers. Further prospective studies are required to determine the risk factors and markers of OBI.

21 October 2016 in Virology Journal
Verified
Journal Article
Open access
PDF file
TMTshifhiwa Magoro
Tshifhiwa Magoro
GGGeorge Gachara
George Gachara
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
ELEmmaculate Lum
Emmaculate Lum
HKHelen K. Kimbi
Helen K. Kimbi
PBPascal Bessong
Pascal Bessong
HBV and HIV share similar transmission routes. Concurrent infection with the two viruses usually results in more severe and progressive liver disease, and a higher incidence of cirrhosis, liver cancer and mortality. Further, this co-infection may lead to cross-resistance between HIV and HBV drugs and increased liver injury, either due to direct hepatotoxicity or drug-related immune-reconstitution hepatitis. These challenges necessitate continuous surveillance for HBV among HIV infected individuals to guide patient management. We conducted this study to understand the serologic and genotypic characteristics of HBV among HIV/HBV infected patients in South West and Littoral Regions of Cameroon. Plasma samples were screened for HBsAg, HBeAg, Anti-HBs and anti-HBc using ELISA followed by DNA extraction from all HBsAg positive samples. A 366 bp region covering the overlapping surface/polymerase gene was amplified by a nested PCR and the product sequenced using Big Dye sequencing chemistry. The resulting sequences were then analyzed for genotypes and both escape and drug resistance mutations. Of the 455 samples in this study, 25.5 % (n = 116) were HBsAg positive and 46 of these had their DNA successfully amplified. Genotype E was found in 32 samples (69.6 %) and genotype A in the rest of the samples. Escape mutations associated with failure of diagnosis (Y100C, R122K and Q129H) and with vaccine escape (Q129R and T131N) were detected in varying frequencies in the population. Polymerase mutations implicated in resistance to lamivudine and other ʟ-nucleoside analogues were detected in seven patients (15.2 %), while all the samples lacked mutations associated with resistance to adefovir and tenofovir. These findings suggest the endemicity of HBV and the predominance of genotypes A and E in the study population. Also, drug resistance findings support the use of tenofovir based ART regimens among HIV/HBV co-infected persons. There is need for continuous HBV screening and monitoring in HIV infected individuals in these regions.

21 August 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
JFJustine Fri
Justine Fri
MRMulalo Raphalalani
Mulalo Raphalalani
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
PBPascal Bessong
Pascal Bessong
Antibiotic resistance is a global health problem. The human gut microbiome is implicated in the dynamics of antibiotic resistance acquisition and transmission, with the gut microbiota thought to play a crucial role. This study aimed to determine the potential influence of the human gut bacteria microbiota on the gut resistome and the relationship between the gut microbiota and Escherichia coli resistome. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline was used to systematically review studies that characterized the gut microbiota and resistome using metagenomic analysis and/or those that reported gut E. coli resistome in healthy individuals. Changes in the diversity and abundance of the bacterial gut microbiota and the resistome across different time points and participant groups were summarized. Additionally, using E. coli resistome as a proxy for the gut resistome, the microbiota composition of the gut harboring antibiotic-resistant E. coli was examined. The findings suggest that lower bacterial microbiota diversity is likely associated with an increased abundance of the overall gut resistome. Age-related differences were observed, with younger infants exhibiting lower microbiota diversity and higher antibiotic resistance gene (ARG) abundance compared to older infants and adults. Studies that reported positive correlations between the relative abundance of Proteobacteria and ARGs were mainly driven by members within the Enterobacteriaceae family, mainly E. coli. This study also reveals that human gut microbiome studies investigating the gut resistome using metagenomic sequencing approaches in healthy individuals are uncommon.

25 October 2023 in Viruses
Verified
Journal Article
Open access
PDF file
LTLisa Arrah Mbang Tambe
Lisa Arrah Mbang Tambe
PMPhindulo Mathobo
Phindulo Mathobo
MMMukhethwa Munzhedzi
Mukhethwa Munzhedzi
PBPascal Bessong
Pascal Bessong
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
Coronaviruses, re-emerging in human populations, cause mild or severe acute respiratory diseases, and occasionally epidemics. This study systematically reviewed human coronavirus (HCoVs) infections in Africa prior to the SARS-CoV-2 outbreak. Forty studies on the prevalence or molecular epidemiology of HCoVs were available from 13/54 African countries (24%). The first published data on HCoV was from South Africa in 2008. Eight studies (20%) reported on HCoV molecular epidemiology. Endemic HCoV prevalence ranged from 0.0% to 18.2%. The prevalence of zoonotic MERS-CoV ranged from 0.0% to 83.5%. Two studies investigated SARS-CoV infection, for which a prevalence of 0.0% was reported. There was heterogeneity in the type of tests used in determining HCoV prevalence. Two studies reported that risk factors for HCoV include exposure to infected animals or humans. The quantity of virologic investigations on HCoV on the African continent was scant, and Africa was not prepared for SARS-CoV-2.

1 March 2022 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
BOBixa Okech Ogola
Bixa Okech Ogola
NMNontokozo Matume
Nontokozo Matume
LMLufuno Grace Mavhandu
Lufuno Grace Mavhandu
DTDenis Manga Tebit
Denis Manga Tebit
PBPascal Bessong
Pascal Bessong
South Africa introduced the “diagnose and treat” HIV treatment programme in September 2016. The programme enables diagnosed HIV positive patients to start treatment. However, the presence of drug resistant (DR) viruses in the drug naïve population complicates the choice of ART. We used next generation sequencing (NGS) to determine the prevalence and diversity of HIV DR mutations in patients entering HIV treatment programmes in northern South Africa. RNA was isolated from the plasma of drug naive HIV-1 infected patients. The HIV-1-pol gene comprising the complete protease (PR) and the first 900bp of reverse transcriptase (RT) was amplified and sequenced on an Illumina MiniSeq platform. Consensus sequences were derived at >20% threshold and at >5% threshold using Geneious PRIME® software version 2020.1.2. HIV-1 surveillance drug resistance mutations (SDRM) were inferred using Calibrated Population Resistance (CPR) tool in HIV Drug Resistance Database. Viral subtypes were determined using REGA and RIP genotyping tools. The HIV PR/RT region was successfully sequenced from 241 patients. From these, 23 (9.5%) had at least one SDRM detected at >20% threshold, with a prevalence of 9.5% (n=18), 3% (n=7) and 0.4% (n=1) for NNRTI, NRTI and PI respectively. The number of patients with SDRM increased to 31 (12.9%) when minority variants were accounted for at >5% threshold. The most frequent SDRMs based on drug class were; K103N (7.9%-NNRTI), K65R (2.5%-NRTI) and D30N (0.8%-PI). Four cases of dual NRTI/NNRTI mutations were identified. All consensus sequences were subtype C except three which were C/A1, C/F1 and C/G recombinants. NGS analysis confirms that individuals entering HIV treatment programmes in northern South Africa, habour moderate levels of SDRM including cases of dual-class drug resistance. Further SDRM studies may be required to better understand resistance in the drug naïve population in the era of “diagnose and treat” in Limpopo province, South Africa.